Literature DB >> 25867048

[S3 guideline hepatitis C addendum].

C Sarrazin1, T Berg2, P Buggisch3, M M Dollinger4, H Hinrichsen5, H Hofer6, D Hüppe7, M P Manns8, S Mauss9, J Petersen3, K-G Simon10, I van Thiel11, H Wedemeyer8, S Zeuzem1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25867048     DOI： 10.1055/s-0034-1399322

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN： 0044-2771            Impact factor:   2.000


× No keyword cloud information.
  13 in total

1.  [Step-by-step toward the perfect hepatitis C treatment for all genotypes].

Authors:  M Cornberg; S Nitschmann
Journal:  Internist (Berl)       Date:  2015-09       Impact factor: 0.743

Review 2.  Antiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma: Indications and Prognosis.

Authors:  Christoph Roderburg; Frank Tacke; Christian Trautwein
Journal:  Visc Med       Date:  2016-04-05

Review 3.  Pre- and Post-Transplant Antiviral Therapy (HBV, HCV).

Authors:  Martin-Walter Welker; Stefan Zeuzem
Journal:  Visc Med       Date:  2016-04-08

Review 4.  Management of HCV-Associated Liver Cirrhosis.

Authors:  Maximilian D Schneider; Christoph Sarrazin
Journal:  Visc Med       Date:  2016-04-08

Review 5.  [Cryoglobulinemic vasculitis].

Authors:  N Blank; H-M Lorenz
Journal:  Z Rheumatol       Date:  2016-04       Impact factor: 1.372

6.  Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals.

Authors:  Fabian Finkelmeier; Georg Dultz; Kai-Henrik Peiffer; Bernd Kronenberger; Franziska Krauss; Stefan Zeuzem; Christoph Sarrazin; Johannes Vermehren; Oliver Waidmann
Journal:  Liver Cancer       Date:  2018-03-01       Impact factor: 11.740

7.  Hepatitis C among healthcare personnel: secondary data analyses of costs and trends for hepatitis C infections with occupational causes.

Authors:  Claudia Westermann; Madeleine Dulon; Dana Wendeler; Albert Nienhaus
Journal:  J Occup Med Toxicol       Date:  2016-11-24       Impact factor: 2.646

8.  Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.

Authors:  Jona T Stahmeyer; Siegbert Rossol; Sebastian Liersch; Ines Guerra; Christian Krauth
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

9.  Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry.

Authors:  Georg Dultz; Tobias Müller; Jörg Petersen; Stefan Mauss; Tim Zimmermann; Marion Muche; Karl-Georg Simon; Thomas Berg; Stefan Zeuzem; Dietrich Hüppe; Klaus Böker; Heiner Wedemeyer; Tania M Welzel
Journal:  Drugs Aging       Date:  2018-09       Impact factor: 4.271

Review 10.  Prevention strategies for blood-borne viruses-in the Era of vaccines, direct acting antivirals and antiretroviral therapy.

Authors:  Stephanie Pfaender; Thomas von Hahn; Joerg Steinmann; Sandra Ciesek; Eike Steinmann
Journal:  Rev Med Virol       Date:  2016-05-17       Impact factor: 6.989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.